Hot Features
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb t... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.00025 | 0.59880239521 | 0.04175 | 0.042 | 0.04175 | 1202 | 0.04175 | CS |
| 4 | 0.0042 | 11.1111111111 | 0.0378 | 0.042 | 0.035 | 23944 | 0.03638749 | CS |
| 12 | -0.007106 | -14.4707367735 | 0.049106 | 0.0521 | 0.035 | 12750 | 0.04091519 | CS |
| 26 | -0.02091 | -33.237958989 | 0.06291 | 0.07618 | 0.035 | 12172 | 0.05363523 | CS |
| 52 | -0.0495 | -54.0983606557 | 0.0915 | 0.12 | 0.035 | 17630 | 0.07286094 | CS |
| 156 | -0.038 | -47.5 | 0.08 | 0.285 | 0.024 | 27060 | 0.10289374 | CS |
| 260 | -0.1671 | -79.9139167862 | 0.2091 | 0.3279 | 0.024 | 22249 | 0.13140013 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.